Please select the option that best describes you:
Topics:
Gynecologic Oncology • Cervical Cancer
Does being on maintenance pembrolizumab change how you manage patients with partial metabolic response on PET/CT 3 months after chemoradiation for cervical cancer?
On the one hand, the addition of immunotherapy should increase a patient's likelihood of treatment response, so perhaps persistent disease in this setting is an even worse prognostic factor. However, the patient will be continuing on systemic therapy far beyond completion of radiation, so do you have a higher "tolerance" for residual disease in this setting and are perhaps less likely to re-biopsy?
Answer from: at Community Practice
No, a good percentage of patients will not have a complete response by 3 months. Six months seems to be a reasonable cutoff. Persistent disease at 3 months does not seem to be a worse prognostic factor than completion at 6 months. At the 3-month mark, I would not manage differently. At 6 months, I w...
I think it depends on what the PET and/or MRI show...